Antiretroviral concentrations in small hair samples as a feasible marker of adherence in rural Kenya

Journal of Acquired Immune Deficiency Syndromes

Volumn 66, Issue 3, 2014, Pages 311-315

  Hickey, Matthew D ^a,b,c   Salmen, Charles R ^a,b,c   Tessler, Robert A ^d   Omollo, Dan ^b   Bacchetti, Peter ^a   Magerenge, Richard ^b   Mattah, Brian ^b   Salmen, Marcus R ^b   Zoughbie, Daniel ^c   Fiorella, Kathryn J ^a,e   Geng, Elvin ^a   Njoroge, Betty ^f   Jin, Chengshi ^a   Huang, Yong ^d   Bukusi, Elizabeth A ^f,g   Cohen, Craig R ^g   Gandhi, Monica ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Mfangano Island Research Group Organic Health Response   (Kenya)

^c Microclinic International (MCI)   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^g Family AIDS Care Education and Services   (Kenya)

Author keywords

Adherence; Feasibility and acceptability; Hair concentrations; Nevirapine; Pharmacologic measure; Resourcelimited setting

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR DISOPROXIL; ZIDOVUDINE; BIOLOGICAL MARKER;

ADULT; AGE; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; DRUG HAIR LEVEL; FEMALE; HAIR ANALYSIS; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KENYA; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGRAM ACCEPTABILITY; PROGRAM FEASIBILITY; RURAL AREA; SELF REPORT; SEX DIFFERENCE; TANDEM MASS SPECTROMETRY; TREATMENT DURATION; VIRUS LOAD; AGED; CHEMISTRY; FEASIBILITY STUDY; HAIR; HIV INFECTIONS; MIDDLE AGED; PROSPECTIVE STUDY; REGRESSION ANALYSIS; REPRODUCIBILITY; RURAL POPULATION; STATISTICS AND NUMERICAL DATA; THIN LAYER CHROMATOGRAPHY; YOUNG ADULT;

ADULT; AGED; ANTI-RETROVIRAL AGENTS; BIOLOGICAL MARKERS; CHROMATOGRAPHY, THIN LAYER; FEASIBILITY STUDIES; FEMALE; HAIR; HIV INFECTIONS; HUMANS; KENYA; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NEVIRAPINE; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; RURAL POPULATION; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 84922392763     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000154     Document Type: Article

References (41)

1. Van Zyl GU, Van Mens TE, McIlleron H, et al. Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting. J Acquir Immune Defic Syndr. 2011;56:333-339.
2. Fabbiani M, Di Giambenedetto S, Bracciale L, et al. Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice. J Antimicrob Chemother. 2009;64:109-117.
3. Li JZ, Gallien S, Ribaudo H, et al. Incomplete adherence to antiretroviral therapy is associated with higher levels of residual HIV-1 viremia. AIDS. 2013;28:181-186.
4. Berg KM, Arnsten JH. Practical and conceptual challenges in measuring antiretroviral adherence. J Acquir Immune Defic Syndr. 2006;43(suppl 1):S79-S87.
5. Kagee A, Nel A. Assessing the association between self-report items for HIV pill adherence and biological measures. AIDS Care. 2012;24:1448-1452.
6. Gandhi M, Greenblatt RM. Hair it is: the long and short of monitoring antiretroviral treatment. Ann Intern Med. 2002;137:696-697.
7. Haberer JE, Kahane J, Kigozi I, et al. Real-time adherence monitoring for HIV antiretroviral therapy. AIDS Behav. 2010;14:1340-1346.
8. Wendel CS, Mohler MJ, Kroesen K, et al. Barriers to use of electronic adherence monitoring in an HIV clinic. Ann Pharmacother. 2001;35:1010-1015.
9. Liu H, Golin CE, Miller LG, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med. 2001;134:968-977.
10. Muller AD, Jaspan HB, Myer L, et al. Standard measures are inadequate to monitor pediatric adherence in a resource-limited setting. AIDS Behav. 2011;15:422-431.
11. Gandhi M, Ameli N, Bacchetti P, et al. Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy. Clin Infect Dis. 2011;52:1267-1275.
12. Gandhi M, Ameli N, Bacchetti P, et al. Protease inhibitor levels in hair strongly predict virologic response to treatment. AIDS. 2009;23:471-478.
13. Huang Y, Gandhi M, Greenblatt RM, et al. Sensitive analysis of anti-HIV drugs, efavirenz, lopinavir and ritonavir, in human hair by liquid chromatography coupled with tandem mass spectrometry. Rapid Commun Mass Spectrom. 2008;22:3401-3409.
14. Huang Y, Yang Q, Yoon K, et al. Microanalysis of the antiretroviral nevirapine in human hair from HIV-infected patients by liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem. 2011;401:1923-1933.
15. Gandhi M, Ameli N, Bacchetti P, et al. Concentrations of efavirenz in hair are strongly correlated with virologic response. 16th Conference on Retroviruses and Opportunistic Infections (CROI); 2009; Montreal, Canada.
16. Gandhi M, Mwesigwa J, Aweeka F, et al. Hair and plasma data show that lopinavir, ritonavir, and efavirenz all transfer from mother to infant in Utero, but only efavirenz transfers via breastfeeding. J Acquir Immune Defic Syndr. 2013;63:578-584.
17. Bartelink IH, Savic RM, Mwesigwa J, et al. Pharmacokinetics of lopinavir/ritonavir and efavirenz in food insecure HIV-infected pregnant and breastfeeding women in Tororo, Uganda. J Clin Pharmacol. 2013.
18. Bernard L, Peytavin G, Vuagnat A, et al. Indinavir concentrations in hair from patients receiving highly active antiretroviral therapy. Lancet. 1998;352:1757-1758.
19. Bernard L, Vuagnat A, Peytavin G, et al. Relationship between levels of indinavir in hair and virologic response to highly active antiretroviral therapy. Ann Intern Med. 2002;137:656-659.
20. Duval X, Peytavin G, Breton G, et al. Hair versus plasma concentrations as indicator of indinavir exposure in HIV-1-infected patients treated with indinavir/ritonavir combination. AIDS. 2007;21:106-108.
21. Servais J, Peytavin G, Arendt V, et al. Indinavir hair concentration in highly active antiretroviral therapy-treated patients: association with viral load and drug resistance. AIDS. 2001;15:941-943.
22. Beumer JH, Bosman IJ, Maes RA. Hair as a biological specimen for therapeutic drug monitoring. Int J Clin Pract. 2001;55:353-357.
23. Kulzer JL, Penner JA, Marima R, et al. Family model of HIV care and treatment: a retrospective study in Kenya. J Int AIDS Soc. 2012;15:8.
24. Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care. 2000;12:255-266.
25. Ickovics JR, Cameron A, Zackin R, et al. Consequences and determinants of adherence to antiretroviral medication: results from Adult AIDS Clinical Trials Group protocol 370. Antivir Ther. 2002;7:185-193.
26. Mannheimer S, Thackeray L, Huppler Hullsiek K, et al. A randomized comparison of two instruments for measuring self-reported antiretroviral adherence. AIDS Care. 2008;20:161-169.
27. Lu M, Safren SA, Skolnik PR, et al. Optimal recall period and response task for self-reported HIV medication adherence. AIDS Behav. 2008;12:86-94.
28. Oyugi JH, Byakika-Tusiime J, Charlebois ED, et al. Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. J Acquir Immune Defic Syndr. 2004;36:1100-1102.
29. Henderson GL. Mechanisms of drug incorporation into hair. Forensic Sci Int. 1993;63:19-29.
30. Gandhi M, Yang Q, Bacchetti P, et al. A low-cost method for analyzing nevirapine levels in hair as a marker of adherence in resource-limited settings. AIDS Res Hum Retroviruses. 2014;30:25-28.
31. Thirumurthy H, Siripong N, Vreeman RC, et al. Differences between self-reported and electronically monitored adherence among patients receiving antiretroviral therapy in a resource-limited setting. AIDS. 2012;26:2399-2403.
32. Wiens MO, MacLeod S, Musiime V, et al. Adherence to antiretroviral therapy in HIV-positive adolescents in Uganda assessed by multiple methods: a prospective cohort study. Paediatr Drugs. 2012;14:331-335.
33. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487-497.
34. Nieuwkerk PT, De Boer-Van Der Kolk IM, Prins JM, et al. Self-reported adherence is more predictive of virological treatment response among patients with a lower tendency towards socially desirable responding. Antivir Ther. 2010;15:913-916.
35. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587-2599.
36. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367:411-422.
37. Salmen C. Towards an Anthropology of Organic Health: The Relational Fields of HIV/AIDS Among the Suba of Lake Victoria: Institute of Social and Cultural Anthropology. Oxford University; 2009.
38. Winston A, Jose S, Gibbons S, et al. Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring. J Antimicrob Chemother. 2013;68:1354-1359.
39. Ortego C, Huedo-Medina TB, Santos P, et al. Sex differences in adherence to highly active antiretroviral therapy: a meta-analysis. AIDS Care. 2012;24:1519-1534.
40. Gandhi M, Aweeka F, Greenblatt RM, et al. Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol. 2004;44:499-523.
41. Hoffmann CJ, Charalambous S, Sim J, et al. Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa. Clin Infect Dis. 2009;49:1928-1935.